OBJECTIVE To determine whether semaglutide slows progression of glycemia in people
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …

OBJECTIVE To evaluate the cardiovascular effects of semaglutide by baseline glycated
hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects …

Aims The once‐weekly administered glucagon‐like peptide 1 (GLP‐1) receptor agonist
(GLP‐1RA) semaglutide, has, in clinical trials, demonstrated significant reductions in …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To …

Abstract Objective In the Semaglutide Treatment Effect in People with obesity (STEP) trials,
once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

OBJECTIVE This analysis of 3,375 adults with overweight/obesity across the Semaglutide
Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials evaluated whether more …

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …

Oral semaglutide is the first oral glucagon‐like peptide‐1 receptor agonist for the treatment
of type 2 diabetes, and showed significant benefits in glycaemic control and weight …